CD274 and esophageal squamous cell carcinoma: Clinically, Programmed Cell Death Ligand 1 (PD-L1) inhibitors combined with chemotherapy have shown promising clinical benefits and represent a new first-line (1L) treatment option for patients with advanced ESCC.